Key result
Intravenous nitroglycerine linked to ~87% higher in-hospital mortality in hypertensive acute heart failure.
Why the study?
To analyse factors associated with adverse events in patients presenting with hypertensive acute heart failure and assess whether differences exist according to patient sex.
Cohort (n=2,865)
Yes
In patients presenting with hypertensive acute heart failure, advanced age is the strongest predictor of mortality, and the use of intravenous nitroglycerine may be associated with increased in-hospital mortality risk.
Answers are grounded in this paper and cite their sources.
Highlights potential sex-specific risk factors for adverse events in hypertensive AHF; leaves open need for prospective validation before practice change.
OBJECTIVE: To analyse the factors associated with adverse events in patients presenting with hypertensive acute heart failure (AHF), and to assess whether differences exist according to patient sex. METHODS: We included patients diagnosed with AHF Spanish emergency departments (EDs), with a decompensation episode and elevated systolic blood pressure (SBP) on arrival. We analysed the association between 22 independent variables and in-hospital mortality. One-year mortality and 30-day post-discharge composite adverse events (defined as ED revisit, hospitalisation, or death) were analysed. RESULTS: We included 2865 AHF episodes secondary to hypertensive crisis (median age: 83 years; 60.5% women). In-hospital mortality was 5.3% and was independently associated with nine variables. Intravenous nitroglycerine administration was associated with increased in-hospital mortality (adjusted OR 1.874; 95% CI: 1.322-2.658). One-year mortality was 23.8% and was associated with eight variables (the same as in-hospital mortality, excluding valvular disease). In both cases, the strongest predictor was age ≥80 years (adjusted OR 2.195 [1.768-2.724]; adjusted HR 1.896 [1.548-2.323], respectively). The 30-day composite adverse event rate was 25.5% and was directly associated with chronic obstructive pulmonary disease (COPD) (HR 1.332; 95% CI: 1.095-1.621) and ischaemic heart disease (HR 1.202; 95% CI: 1.006-1.436), and inversely associated with hospitalisation (HR 0.781; 95% CI: 0.645-0.945). No significant interactions with sex were found for any outcome. CONCLUSIONS: In hypertensive AHF, multiple factors are associated with mortality, and intravenous nitroglycerine use appears to increase risk. Post-discharge adverse events are more frequent in patients with chronic pulmonary and ischaemic heart disease. No sex-based differences were observed for any of the outcomes analysed.
No takes yet. Share an insight, caveat, or question.
Miro et al. (2026) conducted a cohort in hypertensive acute heart failure (n=2,865). Intravenous nitroglycerine was evaluated on In-hospital mortality (adjusted OR 1.874, 95% CI 1.322-2.658). Intravenous nitroglycerine administration in hypertensive acute heart failure was associated with increased in-hospital mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: